Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Auteurs : Strasser-Weippl K, Horick N, Smith IE, O Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE
Jaar : 2015
Journal : Breast Cancer Res
Volume : 17(1)
Pagina's : 56